Clinical Trials for Breast Cancer

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with leptomeningeal disease secondary to breast cancer or non-small cell lung cancer who have adequate performance status and organ function, and treats them with photon craniospinal irradiation using VMAT, an advanced conformal radiation therapy technique. All patients receive 10 fractions of CSI over 10 to 20 days to assess efficacy and safety in controlling central nervous system progression.

ClinicalTrials.gov ID: NCT06910761

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with recurrent or second primary tumors in body sites previously treated with radiotherapy—including CNS, head and neck, breast, thoracic, GI, GU, and gynecological cancers—to evaluate reirradiation using pencil beam scanning proton therapy, which aims to provide effective tumor control with reduced toxicity compared to standard photon techniques. No investigational drugs are included, and some cohorts may not allow concurrent chemotherapy.

ClinicalTrials.gov ID: NCT05313191

A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls patients with locally advanced or metastatic triple-negative breast cancer who have progressed after prior chemotherapy, randomizing them to receive either nanosomal docetaxel lipid suspension (a lipid-based docetaxel formulation designed to reduce toxicity and hypersensitivity) at two different doses or standard docetaxel (Taxotere), with all treatments given every 3 weeks until progression or unacceptable toxicity. Prior docetaxel in the metastatic setting and active CNS metastases (except asymptomatic) are exclusion criteria.

ClinicalTrials.gov ID: NCT03671044

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with ER-positive, HER2-negative advanced or metastatic breast cancer previously treated with endocrine therapy (and CDK4/6 inhibitors depending on arm) to evaluate the safety and efficacy of elacestrant, an oral selective estrogen receptor degrader, in combination with various targeted agents including alpelisib (PI3K inhibitor), everolimus (mTOR inhibitor), palbociclib/abemaciclib/ribociclib (CDK4/6 inhibitors), and capivasertib (AKT inhibitor). Key exclusions are active CNS disease, symptomatic visceral crisis, and prior use of elacestrant or the relevant combination partner in the metastatic setting.

ClinicalTrials.gov ID: NCT05563220

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic melanoma (including those with untreated brain metastases) or triple-negative breast cancer with brain metastases who have progressed after standard therapy, testing the combination of alpelisib (a PI3Kα inhibitor) and pembrolizumab (a PD-1 inhibitor).

ClinicalTrials.gov ID: NCT06545682

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring deleterious germline or somatic DNA damage response (DDR) gene aberrations who have progressed after standard therapy, including those with prior platinum or PARP inhibitor exposure. Patients receive oral talazoparib, a PARP1/2 inhibitor that exploits defective DNA repair in cancer cells, administered daily in 28-day cycles until disease progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT04550494

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic, immunologically cold solid tumors—including biliary tract, HR-negative/HER2-positive breast, platinum-resistant ovarian, pancreatic adenocarcinoma, soft tissue sarcoma, castrate-resistant prostate, neuroendocrine, and vulvar cancers—who have progressed on or are intolerant to standard therapies. Patients receive atezolizumab (anti-PD-L1 immune checkpoint inhibitor) combined with tivozanib (oral VEGFR tyrosine kinase inhibitor), aiming to improve tumor response rates in this refractory population.

ClinicalTrials.gov ID: NCT05000294

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic non-GIST solid tumors (such as melanoma, sarcoma, or primary CNS tumors) harboring activating mutations in CKIT or PDGFRA, who have no effective standard therapy options. Patients receive avapritinib, an oral tyrosine kinase inhibitor selective for CKIT and PDGFRA mutations.

ClinicalTrials.gov ID: NCT04771520

Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls post-menopausal women with endocrine-resistant, advanced or recurrent ER-positive, HER2-negative breast cancer who have had at least one prior endocrine therapy in the advanced setting, testing olaparib (a PARP inhibitor that targets DNA repair defects) in combination with 17b-estradiol followed by 17b-estradiol alone.

ClinicalTrials.gov ID: NCT05900895

Prospective Evaluation of Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor in Hormone Receptor (HR) Positive Metastatic Breast Cancer (MBC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with newly diagnosed or untreated hormone receptor-positive, HER2-negative metastatic or locally advanced breast cancer who are starting first-line endocrine therapy (aromatase inhibitor or fulvestrant) with the CDK4/6 inhibitor palbociclib, or who are adding palbociclib after progression on endocrine therapy. The study involves standard-of-care endocrine therapy plus palbociclib (a cell cycle inhibitor), with serial collection of tumor tissue and blood for molecular profiling.

ClinicalTrials.gov ID: NCT03439735